following a full submission assessed under the orphan equivalent medicine process:
levodopa 20mg/mL + carbidopa monohydrate 5mg/mL + entacapone 20mg/mL intestinal gel (Lecigon®) is not recommended for use within NHSScotland.
Indication under review: treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results.
In a phase I pharmacokinetic study, in patients with advanced levodopa-responsive Parkinson's disease, dose-adjusted levodopa exposure was significantly higher with Lecigon® treatment, when compared with levodopa / carbidopa monohydrate intestinal gel.
The submitting company did not present a sufficiently robust clinical or economic analysis to gain acceptance by SMC.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- levodopa/carbidopa/entacapone (Lecigon)
- SMC ID:
- SMC2507
- Indication:
For treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results
- Pharmaceutical company
- Britannia Pharmaceuticals Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 09 December 2024